Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients

NCT ID: NCT05181046

Last Updated: 2023-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

420 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-06

Study Completion Date

2022-12-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effect of microdrops vs. standard eyedrops of 0.5% timolol maleate in adults with primary open-angle glaucoma or ocular hypertension in terms of intraocular pressure-lowering efficacy and cardiovascular side effects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This randomized, single-masked, parallel study aims to evaluate the safety and efficacy of microdrops of 0.5% timolol maleate administered with Nanodropper (experimental intervention) compared to standard drops of 0.5% timolol maleate (active comparator) in patients with primary open-angle glaucoma (OAG) or ocular hypertension (OHT) at Aravind Eye Hospital. At the beginning of the test day, baseline (pre-drug) intraocular pressure (IOP), resting heart rate (HR), and resting systolic and diastolic blood pressure (BP) measurements will be collected. Participants will be randomized to receive standard eyedrops or microdrops of 0.5% timolol maleate (one drop per eye), which will be administered by a trained technician at t = 0. IOP, HR, and BP measurements will be repeated by a masked investigator at t = 1, 2, 5, and 8 hours after drug administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma Glaucoma, Open-Angle Glaucoma, Primary Open Angle Glaucoma and Ocular Hypertension Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard eyedrops of 0.5% timolol maleate

Participants randomized to this arm will receive one standard drop of 0.5% timolol maleate in each eye.

Group Type ACTIVE_COMPARATOR

Original eyedrop bottle/No Nanodropper

Intervention Type OTHER

The original eyedrop bottle dispenses standard eyedrops.

Nanodropper-mediated microdrops of 0.5% timolol maleate

Participants randomized to this arm will receive one microdrop of 0.5% timolol maleate in each eye. Microdrops will be dispensed from bottles with installed Nanodropper adaptors.

Group Type EXPERIMENTAL

Nanodropper adaptor

Intervention Type DEVICE

The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nanodropper adaptor

The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.

Intervention Type DEVICE

Original eyedrop bottle/No Nanodropper

The original eyedrop bottle dispenses standard eyedrops.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years old
* Recent diagnosis of primary OAG or OHT
* Treatment-naive (not currently using ophthalmic medication)
* Baseline IOP between 21-35 mm Hg
* Corrected Snellen visual acuity of 6/60 or better in each eye

Exclusion Criteria

* \<18 years old
* A recent history (within the past 6 months) of ocular trauma, infection, or uveitis
* Baseline IOP \<21 mm Hg or \>35 mm Hg
* History of cardiovascular, pulmonary, cerebrovascular, or chronic renal disease
* History of borderline or uncontrolled systemic arterial hypertension
* Use of any systemic α-agonist or β-blocker within 30 days of study commencement
* History of receiving general anesthesia within the previous 30 days
* Pregnant women and nursing mothers
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aravind Eye Care System

OTHER

Sponsor Role collaborator

Nanodropper, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jennifer Steger, PhD

Role: STUDY_DIRECTOR

Nanodropper, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aravind Eye Hospital

Madurai, , India

Site Status

Aravind Eye Hospital

Puducherry, , India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

nano001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.